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Changes in the 2009 S.C. List of Reportable Conditions 
As authorized by South Carolina Statute #44-20-
10 and Regulation #61-20, DHEC updates the list 
of Reportable Conditions in January of each year.   
Revisions to the list of reportable conditions are 
based on many factors, including: 1) the need for 
DHEC to conduct surveillance on new conditions or 
to increase surveillance on certain existing 
conditions in order to protect the health of the 
public and 2) changes in reporting requirements 
from the U.S. Centers for Disease Control and 
Prevention (CDC). 
The following revisions have been made to the 
2008 List of Reportable Conditions: 
New for 2009: 
• Influenza deaths (pediatric and adults.) 
Revisions to the List of Reportable 
Conditions: 
• Haemophilus influenzae, non-type b, has 
been changed to “Haemophilus influenzae, 
all types,” and has been moved to Urgently 
Reportable within 24 hours by phone. 
• Influenza, pediatric deaths-age < 17 years 
has been changed to “influenza, deaths 
(pediatric and adults; lab confirmed only: 
(Continued on page 2) 
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1. What are guidelines for use of influenza vaccine in 
pregnancy in the upcoming flu season? 
Vaccination with trivalent inactivated influenza vaccine 
(TIV , or “the flu shot”) is now recommended by the US 
Public Health Service Advisory Committee on Immunization 
Practices (ACIP) for all women who will be pregnant during 
the influenza season (October through mid-May). (1)  
This recommendation is supported by other national organizations 
including the American College of Obstetricians and Gynecologists 
(ACOG). (2)  Table 1 (see page 8) provides historical perspective 
on the evolution of national recommendations over the past two 
decades which has led to current broad guideline for use of TIV in 
pregnancy.    
(Continued on page 8) 
Ask Epi:  
Prevention and Treatment of Influenza during 
Pregnancy 
Eric Brenner, MD, Medical Epidemiologist 
Division of Acute Disease Epidemiology 
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e.g. culture, rapid test, PCR or autopsy 
results consistent with influenza.)” 
• Lead poisoning has been clarified as “lead 
poisoning (elevated blood lead levels, all 
ages.)” 
• Lead tests, all, has been changed to “lead 
tests, all (age < 6).” 
• Legionellosis isolates are now requested; 
footnote (7) has been added to 
Legionellosis. 
• Varicella death has been combined with 
varicella and is listed as “varicella 
(outbreaks and individual cases resulting in 
death or hospitalization.)” 
• Footnote (5) has been updated to clarify 
elevated lead levels. 
• One new footnote has been added: (6) 
defines an outbreak of varicella. 
(Continued from page 1) 
(Continued on page 3) 
Changes in Reporting for Haemophilus influenzae for 2009 
Marya Barker, MPH, Epidemiologist 
Division of Acute Disease Epidemiology 
The 2009 S.C. reporting requirements for varicella 
will change slightly.   
Rather than requiring that all cases of varicella be 
reportable by name, DHEC will require 
reporting of cases by name only in the event 
of outbreaks, hospitalizations and deaths.  
Sporadic cases of varicella will not be 
reportable to DHEC.   
For the purposes of disease reporting, an 
outbreak of varicella is defined as five or 
more cases occurring within six weeks in a 
common setting such as school, childcare or 
other institutional setting. 
As of November 14, 2008, 763 cases of varicella 
had been reported, year to date, to DHEC.  
Previous years’ case counts have been similar.  
The majority of these cases were expected and 
sporadic cases in previously immunized children 
and no public health intervention was necessary.  
Narrowing the criteria for varicella cases to be 
reported will allow public health officials to reserve 
efforts for unusual events that deserve further 
scrutiny and save time for busy providers. 
Changes in Varicella Reporting for 2009 
Marya Barker, MPH, Epidemiologist 
Division of Acute Disease Epidemiology 
For 2009, DHEC has combined the reporting 
for all types of Haemophilus influenzae (H. 
flu), invasive disease into the “Urgently 
Reportable within 24 Hours” category.   
In previous years, DHEC had required immediate 
reporting of H. flu, type b, while non-type b 
disease was reportable within seven days.  The 
primary reason for this change is to reduce 
confusion about reporting requirements for private 
providers and laboratorians. 
In addition, because most private labs in South 
Carolina do not perform serotyping of H. flu 
isolates, providers often waited seven days to 
report positive H. flu tests because the laboratory 
testing indicated only a positive H. flu result.  This 
additional time interval between onset of disease 
and initiation of public health response made the 
timely prophylaxis of contacts difficult and delayed 
or prevented the isolate from being sent to the 
DHEC Bureau of Labs for serotyping.   
We hope that moving all types of H. flu into one 
reporting category will make reporting of H. flu 
easier and faster.  As in the past, all Haemophilus 
influenzae isolates are required to be sent to the 
DHEC Bureau of Labs for serotyping.  These data 
are critical not only for the treatment of the 
patient but also for controlling the potential for 
spread of Hib and for chronicling the changing 
epidemiology of Haemophilus influenzae. 
Changes in the 2009 SC List of Reportable Conditions 
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Changes in the 2009 SC List of Reportable Conditions 
• Under “how to report”, 1. immediately 
reportable conditions, hours have been 
changed to 8:30 AM-5 PM. 
Under “how to report”, 4. HIV and AIDS, “or 
submit electronically via DHEC’s electronic 
reporting system (call 1-800-917-2093 to 
learn more)” has been added. 
Revisions to the Laboratory Reporting List: 
• Haemophilus influenzae, non-type b, has 
been changed to “Haemophilus influenzae, 
all types, and has been moved to Urgently 
Reportable within 24 hours by phone.” 
• Francisella tularensis has been moved to 
Urgently Reportable within 24 hours by 
phone. 
• Lead tests, all other, has been changed to 
“lead tests, all results (ages <6).” 
• Serum lead levels has been changed to 
lead poisoning. 
• Footnote (5) has been updated to clarify 
elevated lead levels. 
Revisions to the Disease Reporting Card: 
• Several sections have been revised to 
include an option for “Unk.”  These include 
ethnicity, pregnant, patient status, 
symptoms for Lyme or RMSF rash and STD 
reporting for treated patients. 
• Specimen type has been changed to 
“specimen source (blood, stool, etc.).” 
The above changes may be found: 
• On the DHEC Web site at: 
http://www.scdhec.gov/  
http://www.scdhec.gov/health/  
http://www.scdhec.gov/health/disease/
index.htm  
• On the 2009 DHEC Disease Reporting Card 
(color is green for 2009.) 
• On the 2009 List of Reportable Conditions 
poster. 
Both the Disease Reporting Cards and the 
laminated Reportable Disease posters (sizes 8½ x 
11 inches and 12 x 24 inches) are available from 
the DHEC regional public health departments or 
from the DHEC Division of Acute Disease 
Epidemiology in Columbia. 
(Continued from page 2) 
2009 DHEC Disease Reporting Card (DHEC 1129 card) 
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Vibrio Spotlight  
Julie Schlegel, MSP, Foodborne Epidemiologist 
Division of Acute Disease Epidemiology 
Vibrio vulnificus is a naturally occurring estuarine 
organism.  Shellfish, such as oysters, may become 
contaminated with Vibrio vulnificus as they feed 
by filtering contaminated seawater.  This is 
especially true of shellfish harvested from the Gulf 
Coast states, which is where the majority of cases 
in the United States occur.  Shellfish sold in South 
Carolina may have been harvested here, but a 
significant percentage will have been imported 
from Gulf Coast states, making Vibrio vulnificus a 
significant concern to our S.C. residents and 
tourists.  
Vibrio vulnificus may cause vomiting, diarrhea, 
and abdominal pain among healthy people who 
eat contaminated seafood.  In the 
immunocompromised, and in those with existing 
chronic illness, Vibrio vulnificus can lead to 
septicemia, causing a severe and life-threatening 
illness.  Vibrio vulnificus bloodstream infections 
are fatal about 50 percent of the time.  
Persons at higher risk for Vibrio vulnificus infection 
include those with liver disorders (e.g., cirrhosis, 
hemochromatosis, chronic hepatitis), diabetes, 
stomach disorders, cancer, HIV/AIDS, alcohol 
abuse and those with weakened immune systems 
due to a variety of medical treatments, such as 
chemotherapy.  Physicians are encouraged to 
warn patients with these risk factors to avoid 
eating raw or undercooked shellfish.  
DHEC staff monitor reports of Vibrio vulnificus.  
When providers report a case of Vibrio vulnificus 
to DHEC a number of processes are set into 
action: 
• An epidemiological interview will be 
conducted to help identify potential sources 
of illness.  If the case reports eating 
shellfish, DHEC staff will conduct a 
traceback of that shellfish to determine the 
harvest site. 
• If any suspect shellfish is available, it will 
be tested. 
• In the case of shellfish contamination, 
DHEC will coordinate with the CDC, the 
FDA and other states to assure that the 
suspect shellfish is no longer available for 
sale and that the harvest site is evaluated. 
Local healthcare providers and laboratories are the 
link between individual presenting patients and 
public health responses.  Without reports of illness 
from local partners, DHEC cannot identify and 
investigate outbreaks of public health significance.  
South Carolina local disease reporters have 
provided key information in numerous outbreak 
investigations and in turn, critical product recalls.  
REPORTING:  Vibrio is reportable within 24 hours 
in South Carolina.  Please see the 2009 S.C. List 
of Reportable Conditions for more information: 
http://www.scdhec.gov/health/disease/docs/
reportable_conditions.pdf.  
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(Continued from page 1) 
It should be noted, however, that unlike TIV, live attenuated (intranasal) influenza vaccine (LAIV) 
is NOT recommended in pregnancy. 
2. Why has national vaccine policy gradually moved to universal influenza vaccination in 
pregnancy?  
The ACIP (1) has cited a number of studies conducted in different settings which have accumulated 
evidence that pregnancy increases influenza complications. (5-9)  Some examples are informally presented 
in Table 2. 
Ask an Epi: Prevention and Treatment of Influenza during Pregnancy 
Table 1: Evolution of ACIP guidelines regarding influenza immunization in 
pregnancy: 2008 and selected illustrative past years 
Year Recommendation for use of TIV in pregnancy 
1993 (3) • Vaccinate only pregnant women with medical conditions known to 
increase risk for complications from influenza. 
1998 (4) • Vaccinate women who will be in the second or third trimester of 
pregnancy during the influenza season.  
• Vaccinate pregnant women who have medical conditions that increase 
their risk of complications from influenza regardless of the stage of 
pregnancy 
2008 (1) • Vaccinate all women who will be pregnant during the influenza season. 
Table 2: 
Reference Study population Conclusion 
5 3975 women consecutively 
delivered at two Nottingham 
hospitals. (British study) 
There was no evidence for transplacental transmission of 
influenza virus. 
There was an increase in complications of pregnancy in the 
influenza cohort 
6 ~25,000 women enrolled in 
Tennessee Medicaid program. 
(Vanderbilt  School of Medicine 
study) 
Out of every 10,000 women in their 3rd trimester without 
other identified risk factors who experience an average 
influenza season of 2.5 months, 25 will be hospitalized with 
influenza related morbidity. 
7 Population-based cohort study of 
pregnant women in Nova Scotia 
(Canadian study) 
Hospitalization rates for respiratory illness among pregnant 
women were ~doubled during influenza season even for 
women without comorbidities.  “All pregnant women are 
likely to benefit from influenza vaccination.” 
8 Review of influenza and pregnant 
women: hospitalization burden, 
USA 1998-2002 (US CDC review) 
Universal vaccination of pregnant women to decrease 
influenza-related morbidity should be encouraged. 
9 National data from the Healthcare 
Cost and Utilization Project National 
Inpatient Sample (NIS). (US CDC 
study) 
During influenza season, hospitalized pregnant women with 
respiratory illnesses had longer lengths of stay and higher 
likelihood of delivery complications.  Interventions to 
decrease influenza-related respiratory morbidity among 
pregnant women ought to be encouraged. 
Representative studies documenting increased complications of influenza 
during pregnancy 
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3. Are antiviral agents for influenza recommended in pregnancy? 
For the general population, annual vaccination remains the primary strategy for preventing morbidity and 
mortality due to influenza.  Antiviral medications may be considered useful adjuncts for prevention of 
influenza and may be effective as treatment when used early in the course of illness. (1)  However, neither 
of the licensed amantadanes (amantadine and rimantadine) is recommended for use in the United States 
because of documented high levels of resistance.  Thus, the neuraminadase inhibitors (oseltamivir and 
zanamivir) are preferred.  Some low-level resistance (~10 percent) of Influenza A H1N1 to oseltamivir 
was documented in the 2007-2008 influenza season, but no cross-resistance to zanamivir was observed.   
Both oseltamivir and zanamivir are “Pregnancy Category C” medications, reflecting the fact that formal 
clinical studies have not been conducted to evaluate their safety in pregnancy.  The ACIP therefore 
recommends that “ …. these two drugs should be used during pregnancy only if the potential benefit 
justifies the potential risk to the embryo or fetus…”   Fortunately, no adverse reactions to these drugs 
have been reported among women who have received them during pregnancy, or among infants born to 
these women. (1)  It appears therefore that these drugs might be used in special situations during 
pregnancy when indicated by informed clinical judgment.  
Published References: 
1. Prevention and Control of Influenza. Recommendations of the ACIP.  MMWR August 8, 2008 / Vol. 57 / No. RR-
7 (available at www.cdc.gov/mmwr).  [The best single document concerning current recommendations.]  
2. ACOG committee opinion number 305, November 2004. Influenza vaccination and treatment during pregnancy.  
Obstet Gynecol. 2004 Nov;104(5 Pt 1):1125-6.  
3. Prevention and Control of Influenza: Part I, Vaccines: Recommendations of the ACIP.  MMWR May 14, 1993 / 
Vol. 42 / No. RR-06. 
4. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices 
(ACIP).  MMWR May 1, 1998 / Vol. 47 / No. RR-06 
5. Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of 
pregnancy: a clinical and seroepidemiological study. BJOG 2000;107:1282–9.  
6. Neuzil KM, Reed GW, Mitchel EF Jr, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary 
hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094–102.  
7. Dodds L, McNeil SA, Fell DB, et al. Impact of influenza exposure on rates of hospital admissions and physician 
visits because of respiratory illness among pregnant women. CMAJ 2007;176:463–8.  
8. Cox S, Posner SF, McPheeters M et al.  Influenza and pregnant women: hospitalization burden, United States, 
1998-2002.  J. Womens Health (Larchmt). 2006 Oct;15(8):891-3 
9. Cox S, Posner SF, McPheeters M et al.  Hospitalizations with respiratory illness among pregnant women during 
influenza season.  Obstet Gynecol. 2006 Jun;107(6):1315-22. 
Selected Web resources concerning influenza: 
(Continued from page 8) 
Ask an Epi: Prevention and Treatment of Influenza during Pregnancy 
• www.cdc.gov/flu/  CDC’s primary “flu portal” with links to numerous general and 
specialized resources 
• www.cdc.gov/flu/about/season/index.htm Useful site to keep up with flu surveillance trends from around the 
country 
• www.nlm.nih.gov/medlineplus/flu.html NIH’s public portal with numerous flu links 
• www.who.int/topics/influenza/en/ Provides an entrée to the World Health Organization’s influenza links 
• www.dhec.sc.gov/flu General information from DHEC about influenza as well as links to 
more specialized information 
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South Carolina 2008-2009 Influenza Season Surveillance Update 
Chasisity Springs, MSPH, Influenza Epidemiologist 
Division of Acute Disease Epidemiology 
1. Changes in the 2009 SC List of Reportable 
Conditions 
The SC 2009 List of Reportable Conditions has 
been updated to make all influenza-related deaths 
reportable.  Previously, influenza-related deaths in 
children < 17 years of age were reportable to the 
local public health department within seven days.  
Beginning in 2009, all (pediatric and adult) lab 
confirmed (culture, rapid test, PCR or autopsy 
results consistent with influenza) influenza deaths 
will be reportable to the local public health 
department within seven days.   
2. SC 2008-2009 Influenza Surveillance 
Update (as of 11/26/2008) 
Influenza surveillance in South Carolina currently 
consists of the following five methodologies: 
a. Rapid Flu Tests  Positive rapid antigen 
influenza tests (total numbers, are reportable 
to regional public health departments within 
seven days) 
b. Viral isolates 
Participation in the viral isolate network is 
FREE.  Providers receive collection kits, lab 
forms, instructions and postage-paid mailers. 
c. Influenza like illness (ILI) 
ILI, or influenza-like illness, is defined as fever 
>100° F AND cough or sore throat where no 
other explanation exists for these symptoms.  
Providers voluntarily submit the number of ILIs 
and the total number of patients seen weekly 
to the CDC via fax or the internet. 
 
(Continued on page 11) 
Epi Notes Winter 2009 Page 11 
SC 2008-2009 Influenza Season Surveillance Update 
d. Enhanced human avian influenza 
surveillance, and  
e. Influenza-associated pediatric deaths, 
which will change in January 2009 to all 
influenza-associated deaths. 
The 2008-2009 influenza season began 
September 28, 2008 (MMWR week 40).  MMWR 
weeks begin on Sunday and end on Saturday.   
Thus far, South Carolina has had 64 positive rapid 
flu tests.  There were 0 positive cultures as of 
MMWR week 47.  Since the beginning of the 2008-
2009 season, the percentage of visits to enrolled 
healthcare providers for influenza-like illness has 
been higher than during the same period in the 
2007-2008 season, with the exception of week 44 
(October 26-November 1, 2008).   
Please visit the DHEC Flu Monitoring Web site for 
weekly updated information:  
www.scdhec.gov/health/disease/acute/flu.htm  
3. Participation in Flu Surveillance 
We reply on our sentinel providers for our flu 
isolate and influenza-like illness data.   
If you wish to participate in the ILI sentinel 
provider network or in the Viral Isolate 
network, contact Chasisity Springs at (803) 898-
0870.   
(Continued from page 10) 
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We are writing to let providers know about using 
the CHESS (Carolina’s Health Electronic 
Surveillance System) for disease reporting.  The 
CHESS system gives you and your practice the 
opportunity to submit required state disease 
reporting electronically.  This option makes 
reporting much faster and easier for your staff.  
As you are aware, healthcare providers are 
required by S.C. law to report specific 
communicable diseases.  Routine disease 
reporting serves several purposes, including but 
not limited to: 
• Identification of clusters, outbreaks and/or 
pandemics, 
• Enabling preventive or mitigative treatments, 
and 
• Assisting in national and international 
surveillance efforts to control the spread of 
diseases. 
Web-based electronic surveillance is a key 
component of S.C. DHEC’s efforts to assure 
timeliness and accuracy in disease reporting.  We 
are excited about finally having in place an easy-
to-use system that has the capacity to receive 
information electronically from private providers 
about a patient’s health status.  
As we know, and as we have heard from you, 
the manual card-based process of disease 
reporting has become 
outdated.  In the past two 
years, DHEC has developed 
systems to accept electronic 
laboratory reports (ELRs) from 
several commercial and reference 
laboratories.  ELRs have greatly 
enhanced DHEC’s ability to 
identify disease burden, to 
address healthcare- and 
community-associated infections 
and to provide timely response to 
single cases of illness that may have 
consequences for a community (e.g., acute 
Hepatitis A or Acute Hepatitis B cases.) 
For healthcare providers, CHESS integrates 
disease reporting to DHEC with data collection by 
DHEC.  CHESS allows participating healthcare 
providers to input a patient’s demographics, 
lab results, and disease history in a timely 
and efficient manner using a web browser.  
Reporting can be done by trained, authorized 
office personnel.  Data provided to CHESS can 
be used to develop customized reports addressing 
trends gathered from disease reporting — one of 
the biggest benefits for providers reporting via 
CHESS. 
CHESS offers providers: 
; Faster and more complete disease reporting 
; Use of industry standards for data 
management 
; A common location in which data are stored 
; Secure handling of confidential data 
; A web-based interface with no need to 
purchase or install specialized software 
Currently, CHESS is used for routine disease 
reporting by a diverse group of providers, 
including hospitals, independent labs, educational 
institutions, private practices and military bases.  
We hope you will consider joining this group. 
Want to know more?  If you 
are a healthcare provider or 
someone who would like to know 
more about the Carolina’s Health 
Electronic Surveillance System, 
contact your Regional Disease 
Response and Surveillance 
Coordinator at the local public 
health department (see list of 
numbers on Page 6.)  You may 
also call 1-800-917-2093 to 
schedule a demonstration. 
Better, Faster, Smarter: Using CHESS for Reportable Conditions 
James J. (Jerry) Gibson, MD, MPH 
State Epidemiologist,  
Director,  
DHEC Bureau of Disease Control  
Denise Brown, MHA 
CHESS/CARES Instructor-
Training Coordinator 
Lisa Still 
Cares IR/CHESS Training and 
Development Director 
Division of Acute Disease 
Epidemiology 
Division of Acute Disease 
Epidemiology 
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Did You Know… 
• PAN FLU HITS COMMUNITIES IN WAVES . .  
• Each wave lasts at least 6 weeks... 
• MEDICAL OFFICES MAY SEE AN EXTRA 25  PATIENTS A DAY . . . 
• 15% to 30% of  the healthcare workforce may be sick 
during pandemic waves?    
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Public Health Clinical Liaisons can provide FREE  Pan Flu 
Informational & Planning Sessions for Medical Practices 
concerning: 
Would you like to have a DHEC Public Health Clinical Liaison visit your practice 
or facility?   
Please provide facility name, county and phone number to: 
Roscia Hardee RN, MPH at 803-898-1490. 
Is your practice prepared for an influenza 
pandemic or for a bad flu season? 
DHEC’s Public Health Clinical Liaisons 
can help! 
• CONTINUITY OF OPERATIONS 
• How will YOU keep your office practice going?  
• INFECTION CONTROL STRATEGIES 
• In Medical Offices and for Patients 
• In the Community 
• INFLUENZA MONITORING SYSTEM ENROLLMENT 
• Flu-like Syndromes 
• Flu Cultures  
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Summary of Conditions reported to SC DHEC January 1 through November 1, 2008.  
Compiled by Claire Youngblood, MA, Data Manager 
Division of Acute Disease Epidemiology 
Condition Confirmed Probable Total 
Animal Bite, PEP Recommended 309 0 309 
Aseptic meningitis 103 1 104 
Botulism, infant 1 0 1 
Brucellosis 1 1 2 
Campylobacteriosis 216 0 216 
Ciguatera fish poisoning 0 0 0 
Cholera 1 0 1 
Cryptosporidiosis 47 3 50 
Cyclosporiasis 1 0 1 
Dengue Fever 0 1 1 
Ehrlichiosis, chaffeensis 0 1 1 
Encephalitis, West Nile 0 0 0 
Enterohem. E. coli O157:H7 1 0 1 
Enterohem. E. coli shigatox+- ?serogrp 1 0 1 
Enterohem. E. coli- shigatox+- non-O157 0 0 0 
Giardiasis 110 1 111 
Group A Streptococcus, invasive 60 0 60 
Group B Streptococcus, invasive 40 0 40 
Haemophilus influenzae, invasive 44 1 45 
Hansen disease (Leprosy) 1 0 1 
Hemolytic uremic syndrome, postdiarrheal 1 0 1 
Hepatitis A, acute 15 0 15 
Hepatitis B, acute 52 1 53 
Hepatitis B virus infection, Chronic 98 415 513 
Hepatitis B virus infection, Perinatal 0 0 0 
Hepatitis C, acute 3 0 3 
Hepatitis C Virus Infection, past or present 3,555 105 3.660 
Hepatitis Delta co- or super-infection, acute 0 0 0 
Hepatitis E, acute 0 0 0 
Influenza, human isolates 254 0 254 
Legionellosis 13 0 13 
Listeriosis 4 0 4 
Lyme disease 10 12 22 
Epi Notes Winter 2009 Page 15 
Summary of Conditions reported to SC DHEC January 1 through November 1, 2008  
Condition Confirmed Probable Total 
Malaria 8 0 8 
Mumps 0 0 0 
Neisseria meningitidis, invasive (Mening. disease) 18 1 19 
Pertussis 90 14 104 
Rocky Mountain spotted fever 6 48 54 
S. aureus, vancomycin intermediate susc (VISA) 0 0 0 
Salmonellosis 1,019 3 1,022 
Shiga toxin-producing Escherichia coli (STEC) 35 3 38 
Shigellosis 495 11 506 
Strep pneumoniae, invasive 451 0 451 
Streptococcal disease, invasive, other 1 0 1 
Tetanus 0 0 0 
Toxic-shock syndrome, staphylococcal 0 0 0 
Typhoid fever (Salmonella typhi) 2 0 2 
Varicella (Chickenpox) 413 335 748 
Vibrio parahaemolyticus 3 0 3 
Vibrio spp., non-toxigenic, other or unspecified 5 0 5 
Vibrio vulnificus infection 3 0 3 
West Nile Fever 0 2 2 
Yersiniosis 5 0 5 
The information below appeared in the Winter 2008 
edition of the Epi Notes.  It is re-printed here for the 
benefit of our new reporting partners. 
In 2008, S.C. DHEC introduced a separate List of 
Reportable Conditions for Laboratories. The 
purpose of this list is to reduce confusion 
regarding disease reporting responsibilities.  
The List of Reportable Conditions for Laboratories 
includes the reportable conditions for which there 
is a laboratory test.  The list is conveniently 
divided into categories of Bacterial, Viral, 
Parasitic, and Other.  The few reportable 
conditions omitted from the laboratory list are 
those in which diagnosis is made based on clinical 
data, e.g., hemolytic uremic syndrome (HUS) or 
conditions that result in death, e.g. varicella or 
influenza deaths. 
Outbreaks, unusual disease and clusters of cases 
remain as reportable situations on the laboratory 
list; however, the terminology “foodborne 
outbreaks” was omitted since the laboratorian is 
not likely to know the source of infection. 
Many other states have already developed 
separate lists for clinicians and labs.  The hope is 
that by targeting different audiences with 
information based on their focus area, reporting 
will be easier and faster than ever. 
List of Reportable Conditions for Laboratories 
Marya Barker, MPH, Epidemiologist 
Division of Acute Disease Epidemiology 
Julie Schlegel, MSP, Foodborne Epidemiologist 
Division of Acute Disease Epidemiology 
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FOR DISEASE REPORTING 
For immediately reportable conditions, call your local county 
health department or, for after hours, call 1-888-847-0902.  
Routine reports may be phoned in to your local health 
department or mailed on a completed DHEC DISEASE 
REPORTING CARD (DHEC 1129.)  Local county health 
department numbers are listed on the Official List of 
Reportable Conditions.   
For a copy of the current Official List of Reportable 
Conditions, call 803-898-0861 or visit www.scdhec.gov/
health/disease.index.htm.  
Bureau of Disease Control 
J. Gibson, MD, MPH, Director 
803-898-0861 
Bureau of Disease Control Divisions 
Division of Acute Disease Epidemiology 
803-898-0861 
Division of Immunization 
1-800-277-4687 
Division of STD/HIV 
803-898-0749 
Division of Surveillance and Technical Support 
803-898-0749 
Division of Tuberculosis Control 
803-898-0558 
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